- Home
- IMMP vs ATNM Comparison
IMMP vs ATNM Comparison
Compare IMMP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- ATNM
- Stock Information
- Founded
- IMMP 1987
- ATNM 2000
- Country
- IMMP Australia
- ATNM United States
- Employees
- IMMP N/A
- ATNM N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- ATNM Health Care
- Exchange
- IMMP Nasdaq
- ATNM Nasdaq
- Market Cap
- IMMP 299.2M
- ATNM 56.5M
- IPO Year
- IMMP N/A
- ATNM N/A
- Fundamental
- Price
- IMMP $1.99
- ATNM $1.73
- Analyst Decision
- IMMP Buy
- ATNM Strong Buy
- Analyst Count
- IMMP 2
- ATNM 5
- Target Price
- IMMP $8.00
- ATNM $14.20
- AVG Volume (30 Days)
- IMMP 85.0K
- ATNM 285.8K
- Earning Date
- IMMP 10-22-2024
- ATNM 10-31-2024
- Dividend Yield
- IMMP N/A
- ATNM N/A
- EPS Growth
- IMMP N/A
- ATNM N/A
- EPS
- IMMP N/A
- ATNM N/A
- Revenue
- IMMP $2,563,302.00
- ATNM $81,000.00
- Revenue This Year
- IMMP $4.79
- ATNM $186.10
- Revenue Next Year
- IMMP N/A
- ATNM $19,248.94
- P/E Ratio
- IMMP N/A
- ATNM N/A
- Revenue Growth
- IMMP 9.59
- ATNM 80.00
- 52 Week Low
- IMMP $1.58
- ATNM $1.33
- 52 Week High
- IMMP $3.34
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- IMMP 35.39
- ATNM 41.48
- Support Level
- IMMP $1.99
- ATNM $1.48
- Resistance Level
- IMMP $2.12
- ATNM $1.80
- Average True Range (ATR)
- IMMP 0.08
- ATNM 0.12
- MACD
- IMMP -0.01
- ATNM 0.04
- Stochastic Oscillator
- IMMP 10.00
- ATNM 54.44
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.